Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer
- Authors
- Sim, EJ[Sim, Eun Ji]; Ko, KP[Ko, Kwang-Pil]; Ahn, C[Ahn, Choonghyun]; Park, SM[Park, Sang Min]; Surh, YJ[Surh, Young-Joon]; An, S[An, Seokyung]; Kim, SW[Kim, Sung-Won]; Lee, MH[Lee, Min-Hyuk]; Lee, JW[Lee, Jong Won]; Lee, JE[Lee, Jeong Eon]; Kim, KS[Kim, Ku Sang]; Yom, CK[Yom, Cha Kyong]; Kim, HA[Kim, Hyun-Ah]; Park, SK[Park, Sue K.]
- Issue Date
- Nov-2020
- Publisher
- SPRINGER
- Keywords
- Hereditary breast cancer syndrome; Familial breast cancer; BRCAmutation; Isoflavones; Soy; Molecular subtypes
- Citation
- BREAST CANCER RESEARCH AND TREATMENT, v.184, no.2, pp.615 - 626
- Indexed
- SCIE
SCOPUS
- Journal Title
- BREAST CANCER RESEARCH AND TREATMENT
- Volume
- 184
- Number
- 2
- Start Page
- 615
- End Page
- 626
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/2714
- DOI
- 10.1007/s10549-020-05875-0
- ISSN
- 0167-6806
- Abstract
- Purpose We investigated the association between isoflavone (ISF) intake and hereditary breast cancer (BC) risk, particularly by molecular subtype, in East-AsianBRCA1/2mutation carriers and non-carriers at a high risk of hereditary breast cancer (i.e., family history of BC (FHBC) and early-onset BC [EOBC, age < 40 years]). Methods The association between ISF intake and BC risk by molecular subtypes was assessed in 1709 participants (407BRCA1/2carriers, 585 FHBC non-carriers, 586 EOBC non-carriers, and 131 unaffected non-carriers) from the Korean Hereditary Breast Cancer Study using hazard ratios (HRs) and 95% confidence intervals (CIs) in weighted Cox regression models. Daily ISF intake was assessed using a validated food frequency questionnaire. We evaluated gene-environment interactions betweenBRCA1/2mutation and ISF intake in 1604 BC cases by calculating the case-only odds ratios (CORs) and 95% CIs in logistic regression models. Results ISF intake was inversely associated with luminal A BC risk inBRCA2mutation carriers and FHBC non-carriers (HR = 0.14, 95% CI = 0.04-0.50 for high intake [ISF intake >= 15.50 mg/day]; HR = 0.27, 95% CI = 0.11-0.69 for high intake, respectively). We observed a reduced risk of triple negative BC (TNBC) inBRCA1carriers and FHBC non-carriers (HR = 0.09, 95% CI = 0.02-0.40 for high intake; HR = 0.19, 95% CI = 0.05-0.69 for high intake, respectively). In the case-only design, an interaction betweenBRCA1mutation carrier status and ISF intake emerged in TNBC patients (COR = 0.39, 95% CI = 0.16-0.95). Conclusions This study suggests that ISF intake is inversely associated with BC risk in women at high risk of hereditary BC and that the effect could differ by molecular subtypes.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.